Exploratory study to evaluate the acceptability of a wearable accelerometer to assess motor progression in motor neuron disease.
Accelerometer
Digital health
Motor neuron disease
Wearable devices
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
28 May 2024
28 May 2024
Historique:
received:
27
09
2023
accepted:
14
05
2024
revised:
10
05
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
28
5
2024
Statut:
aheadofprint
Résumé
Motor neuron disease (MND) is a rapidly progressive condition traditionally assessed using a questionnaire to evaluate physical function, the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R). Its use can be associated with poor sensitivity in detecting subtle changes over time and there is an urgent need for more sensitive and specific outcome measures. The ActiGraph GT9X is a wearable device containing multiple sensors that can be used to provide metrics that represent physical activity. The primary aim of this study was to investigate the initial suitability and acceptability of limb-worn wearable devices to group of people with MND in Scotland. A secondary aim was to explore the preliminary associations between the accelerometer sensor data within the ActiGraph GT9X and established measures of physical function. 10 participants with MND completed a 12-week schedule of assessments including fortnightly study visits, both in-person and over videoconferencing software. Participants wore the device on their right wrist and right ankle for a series of movements, during a 6-min walking test and for a period of 24-h wear, including overnight. Participants also completed an ALSFRS-R and questionnaires on their experience with the devices. 80% of the participants found wearing these devices to be a positive experience and no one reported interference with daily living or added burden. However, 30% of the participants experienced technical issues with their devices. Data from the wearable devices correlated with established measures of physical function.
Identifiants
pubmed: 38805054
doi: 10.1007/s00415-024-12449-3
pii: 10.1007/s00415-024-12449-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Andrews JA et al (2020) Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. https://doi.org/10.1080/21678421.2020.1771734
doi: 10.1080/21678421.2020.1771734
pubmed: 33602018
pmcid: 8117790
Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27(10):1918–1929
doi: 10.1111/ene.14393
pubmed: 32526057
pmcid: 7540334
Rooney J et al (2017) What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 88(5):381–385
doi: 10.1136/jnnp-2016-314661
pubmed: 27888187
Paganoni S, Cudkowicz M, Berry JD (2014) Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig 4(7):605
doi: 10.4155/cli.14.52
Proudfoot M et al (2016) The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener 17(5–6):414–425
doi: 10.3109/21678421.2016.1140786
pubmed: 26864085
pmcid: 4950444
Ramamoorthy D et al. (2021) Identifying patterns of ALS progression from sparse longitudinal data. medRxiv p. 2021.05. 13.21254848
Bedlack RS et al (2016) How common are ALS plateaus and reversals? Neurology 86(9):808–812
doi: 10.1212/WNL.0000000000002251
pubmed: 26658909
pmcid: 4793781
Lu R et al (2020) Evaluation of wearable sensor devices in Parkinson’s disease: a review of current status and future prospects. Parkinson’s Dis. https://doi.org/10.1155/2020/4693019
doi: 10.1155/2020/4693019
Sparaco M et al (2018) The role of wearable devices in multiple sclerosis. Multiple Scler Int. https://doi.org/10.1155/2018/7627643
doi: 10.1155/2018/7627643
Rozanski GM et al (2018) Consumer wearable devices for activity monitoring among individuals after a stroke: a prospective comparison. JMIR Cardio 2(1):e8199
doi: 10.2196/cardio.8199
Gupta AS et al (2023) At-home wearables and machine learning sensitively capture disease progression in amyotrophic lateral sclerosis. Nat Commun 14(1):5080
doi: 10.1038/s41467-023-40917-3
pubmed: 37604821
pmcid: 10442344
van Eijk RPA et al (2019) Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study. J Neurol 266(10):2387–2395
doi: 10.1007/s00415-019-09427-5
pubmed: 31187191
pmcid: 6765690
Kelly M et al (2020) The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 21(7–8):563–573
doi: 10.1080/21678421.2020.1773501
pubmed: 32573278
Holdom CJ et al (2023) Use of hip-versus wrist-based actigraphy for assessing functional decline and disease progression in patients with motor neuron disease. J Neurol 270(5):2597–2605
doi: 10.1007/s00415-023-11584-7
pubmed: 36740646
pmcid: 10129939
Vieira FG et al (2022) A machine-learning based objective measure for ALS disease severity. NPJ Digit Med 5(1):1–9
doi: 10.1038/s41746-022-00588-8
Vieira FG et al (2022) A machine-learning based objective measure for ALS disease severity. NPJ Digit Med 5(1):45
doi: 10.1038/s41746-022-00588-8
pubmed: 35396385
pmcid: 8993812
Leighton D et al (2019) Clinical audit research and evaluation of motor neuron disease (CARE-MND): a national electronic platform for prospective, longitudinal monitoring of MND in Scotland. Amyotroph Lateral Scler Frontotemporal Degener 20(3–4):242–250
doi: 10.1080/21678421.2019.1582673
pubmed: 30889975
Russo M et al (2020) The 6-min walk test as a new outcome measure in amyotrophic lateral sclerosis. Sci Rep 10(1):1–9
doi: 10.1038/s41598-020-72578-3
Leighton DJ et al (2023) Genotype–phenotype characterisation of long survivors with motor neuron disease in Scotland. J Neurol 270(3):1702–1712
doi: 10.1007/s00415-022-11505-0
pubmed: 36515702
van Eijk RP et al. (2021) An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration 22:1–8
Hobson EV et al (2017) “Anything that makes life’s journey better.” Exploring the use of digital technology by people living with motor neurone disease. Amyotroph Lateral Scler Frontotemporal Degener 18(5–6):378–387
doi: 10.1080/21678421.2017.1288253
pubmed: 28631958
Beswick E et al. (2022) A systematic review of digital technology to evaluate motor function and disease progression in motor neuron disease. J Neurol 269:1–15
Chipika RH et al (2019) Tracking a fast-moving disease: longitudinal markers, monitoring, and clinical trial endpoints in ALS. Front Neurol 10:229
doi: 10.3389/fneur.2019.00229
pubmed: 30941088
pmcid: 6433752
Rutkove SB et al (2019) ALS longitudinal studies with frequent data collection at home: study design and baseline data. Amyotroph Lateral Scler Frontotemporal Degener 20(1–2):61–67
doi: 10.1080/21678421.2018.1541095
pubmed: 30486680
Fournier CN et al (2020) Development and validation of the rasch-built overall amyotrophic lateral sclerosis disability scale (ROADS). JAMA Neurol 77(4):480–488
doi: 10.1001/jamaneurol.2019.4490
pubmed: 31886839
Fang T, Jozsa F, Al-Chalabi A (2017) Nonmotor symptoms in amyotrophic lateral sclerosis: a systematic review. Int Rev Neurobiol 134:1409–1441
doi: 10.1016/bs.irn.2017.04.009
pubmed: 28805578
Godkin FE et al. (2021) Feasibility of a continuous, multi-sensor remote health monitoring approach in persons living with neurodegenerative disease. J Neurol 269:1–14
Garcia-Gancedo L et al (2019) Objectively monitoring amyotrophic lateral sclerosis patient symptoms during clinical trials with sensors: observational study. JMIR Mhealth Uhealth 7(12):e13433
doi: 10.2196/13433
pubmed: 31859676
pmcid: 6942190
Thompson M (2021) The environmental impacts of digital health. Digit Health 7:20552076211033420
pubmed: 34408902
pmcid: 8365173
Ngueleu A-M et al (2022) Criterion validity of ActiGraph monitoring devices for step counting and distance measurement in adults and older adults: a systematic review. J Neuroeng Rehabil 19(1):112
doi: 10.1186/s12984-022-01085-5
pubmed: 36253787
pmcid: 9575229
Veerubhotla A et al (2020) Estimation of physical activity intensity in spinal cord injury using a wrist-worn ActiGraph monitor. Arch Phys Med Rehabil 101(9):1563–1569
doi: 10.1016/j.apmr.2020.05.014
pubmed: 32502566
Johnson SA, Karas M, Burke KM, Straczkiewicz M, Scheier ZA, Clark AP, Iwasaki S et al (2023) Wearable device and smartphone data quantify ALS progression and may provide novel outcome measures. NPJ Digit Med 6(1):34
doi: 10.1038/s41746-023-00778-y
pubmed: 36879025
pmcid: 9987377
Ortega-Hombrados L, Molina-Torres G, Galán-Mercant A, Sánchez-Guerrero E, González-Sánchez M, Ruiz-Muñoz M (2021) Systematic review of therapeutic physical exercise in patients with amyotrophic lateral sclerosis over time. Int J Environ Res Public health 18(3):1074
doi: 10.3390/ijerph18031074
pubmed: 33530383
pmcid: 7908444
Keogh A et al (2023) Acceptability of wearable devices for measuring mobility remotely: observations from the mobilise-D technical validation study. Digital Health 9:20552076221150744
doi: 10.1177/20552076221150745
pubmed: 36756644
pmcid: 9900162